July 2025 in “SKIN The Journal of Cutaneous Medicine” Oral minoxidil can help regrow hair lost from antibody-drug conjugate treatment.
1 citations
,
May 2025 in “Frontiers in Medicine” Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.
May 2026 in “Bioorganic Chemistry”
September 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
2 citations
,
October 2022 in “British journal of haematology” A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.
11 citations
,
July 2020 in “Journal of Cosmetic Dermatology” Sandalore® improves hair growth and quality in people with hair loss.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
8 citations
,
June 2022 in “Frontiers in Medicine” Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
45 citations
,
August 2005 in “Bioorganic & medicinal chemistry” New compounds with carborane showed anti-androgen effects similar to flutamide.
2 citations
,
January 2007 in “edoc (University of Basel)” Piper cubeba and Aquilaria sinensis may help prevent or treat prostate issues by balancing hormones.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
3 citations
,
August 2019 in “Medika Tadulako: Jurnal Ilmiah Kedokteran Fakultas Kedokteran dan Ilmu Kesehatan” A 3% hair tonic with bitter melon leaf and carrot extracts boosts hair growth effectively.
August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
1 citations
,
November 2025 in “Journal of the American Academy of Dermatology” 1 citations
,
July 2021 in “Acta dermatovenerologica Croatica” Adalimumab significantly improved symptoms and quality of life in two patients with Hidradenitis Suppurativa.
Baricitinib showed mixed results in treating alopecia areata in children, with some improvement but also side effects.
6 citations
,
August 2017 in “Physiological Research” Setipiprant may reduce inflammation by blocking an enzyme called aldose reductase.
December 2025 in “Orvosi Hetilap” Baricitinib is effective and safe for treating alopecia areata.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
March 2026 in “Stem Cell Reviews and Reports” High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
1 citations
,
September 2025 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.
December 2024 in “Frontiers in Pediatrics” Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
20 citations
,
January 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is the most effective treatment for alopecia areata.
5 citations
,
December 2022 in “Viruses” Antiandrogens may help prevent or treat COVID-19 by blocking virus entry into cells.
52 citations
,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
61 citations
,
January 1970 in “Toxicology and Applied Pharmacology”
Some dermatologists in Saudi Arabia prescribe Tofacitinib for hair loss, but many don't due to its unavailability and safety concerns.